Pharmaceutical - Pharmaceutical, Neurological

Filter

Popular Filters

1 to 25 of 777 results

ADHD treatment market set to reach $9.9 billion by 2020

ADHD treatment market set to reach $9.9 billion by 2020

22-08-2014

The attention-deficit hyperactivity disorder (ADHD) therapeutics market value will rise from $6.9 billion…

ADHDEuropeJapanNeurologicalPharmaceuticalPsychiatryUSA

US federal court issues restraining order against FDA's approval for generics of Hospira's Precedex

US federal court issues restraining order against FDA's approval for generics of Hospira's Precedex

21-08-2014

A judge in US federal court has issued a temporary restraining order following the US Food & Drug Administration’s…

Food and Drug AdministrationHospiraMylanNeurologicalPharmaceuticalPrecedexUSA

Depomed prevails in Gralise ANDA litigation with Actavis

Depomed prevails in Gralise ANDA litigation with Actavis

20-08-2014

US drug maker Depomed saw its shares climb more than 12% to $14.76 on Tuesday, on the news that the firm…

ActavisDepomedGraliseLegalNeurologicalPatentsPharmaceuticalUSA

Belsomra could become first-line insomnia therapy, says GlobalData

Belsomra could become first-line insomnia therapy, says GlobalData

18-08-2014

Insomnia treatment Belsomra (suvorexant) from US pharma giant Merck & Co has the potential to become…

BelsomraChemistryCyclopyrrolonesInsomniaMarkets & MarketingMerck & CoNeurologicalOrganic chemistryPharmaceuticalUSA

IQWiG again turns down Eisai’s epilepsy drug Fycompa

IQWiG again turns down Eisai’s epilepsy drug Fycompa

17-08-2014

The German Institute for Quality and Efficiency in Healthcare (IQWiG) has said that epilepsy drug Fycompa…

EisaiEpilepsyFycompaGermanyNeurologicalPharmaceuticalPricingRegulation

Alexza updates on the five post-EMA approval studies for Adasuve

Alexza updates on the five post-EMA approval studies for Adasuve

14-08-2014

US drugmaker Alexza Pharmaceuticals has provided an update on its European Medicines Agency post-approval…

AdasuveAlexza PharmaceuticalEuropeNeurologicalPharmaceuticalPiperazinesPsychiatryRegulationResearch

Merck’s Belsomra gets FDA approval for insomnia

Merck’s Belsomra gets FDA approval for insomnia

14-08-2014

Pharma giant Merck & Co has received US Food and Drug Administration approval for its insomnia treatment…

BelsomraMerck & CoNeurologicalPharmaceuticalRegulationSedativesUSA

New treatments will partially compensate for unipolar depression drugs coming out of patent

New treatments will partially compensate for unipolar depression drugs coming out of patent

14-08-2014

New antidepressants and antipsychotics will offset a steep decline in sales following genericization…

Antidepressant therapiesDecision Resources GroupGlobalMarkets & MarketingNeurologicalPharmaceuticalPsychiatryUnipolar depression

Australia pledges funding to find dementia breakthrough

Australia pledges funding to find dementia breakthrough

08-08-2014

The Australian Minister for Health, Peter Dutton, has announced the opening of a new round of dementia…

AustraliaCognitive disordersDementiaNeurologicalPharmaceuticalResearch

Teva to sue Dr Reddy’s over Copaxone patent infringement

Teva to sue Dr Reddy’s over Copaxone patent infringement

08-08-2014

Global generics leader Teva Pharmaceutical Industries yesterday confirmed that it has received the first…

CopaxoneDr Reddy's LaboratoriesLegalNeurologicalPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Multiple sclerosis treatments funding proposal in New Zealand

Multiple sclerosis treatments funding proposal in New Zealand

07-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a funding proposal involving…

Biogen IdecFinancialGilenyaNeurologicalNew ZealandNovartisPharmaceuticalTysabri

Eisai's Fycompa launches in Belgium for partial-onset seizures

Eisai's Fycompa launches in Belgium for partial-onset seizures

04-08-2014

Fycompa (perampanel), an epilepsy drug developed by Japanese dug major Eisai, launches today in Belgium.

BelgiumCentral nervous systemEisaiEpilepsyFycompaJapanNeurologicalPharmaceuticalRegulation

French regulators push for huge cut in hypnotic benzodiazepine reimbursement

French regulators push for huge cut in hypnotic benzodiazepine reimbursement

01-08-2014

French regulators are attempting to discourage the over-consumption and misuse of hypnotic benzodiazepines…

diazepamFranceFrench governmentNeurologicalPharmaceuticalRegulation

FDA performs inspection of Impax's Taiwan facility

FDA performs inspection of Impax's Taiwan facility

30-07-2014

The US Food and Drug Administration has performed a general Good Manufacturing Practices (GMP) inspection…

Impax LaboratoriesNeurologicalPharmaceuticalRegulationRytaryUSA

Canada’s Health Minister moves on safe prescribing practices for drugs prone to abuse

Canada’s Health Minister moves on safe prescribing practices for drugs prone to abuse

29-07-2014

Canada’s Minister of Health, Rona Ambrose, has issued a national Call for Proposals to improve the…

CanadaNeurologicalPharmaceuticalRegulation

Reckitt Benckiser to spin out pharma; GSK views Consumer options

Reckitt Benckiser to spin out pharma; GSK views Consumer options

28-07-2014

UK-based consumer goods giant Reckitt Benckiser plans to spin off its USA-based pharmaceutical business,…

FinancialGlaxoSmithKlineMergers & AcquisitionsNeurologicalPharmaceuticalReckitt BenckiserSuboxoneUK

AcelRx Pharma’s Zalviso approval delayed by FDA

AcelRx Pharma’s Zalviso approval delayed by FDA

28-07-2014

USA-based specialty pharma firm AcelRx Pharmaceuticals says that the US Food and Drug Administration…

AcelRxFood and Drug AdministrationNeurologicalPharmaceuticalRegulationUSAZalviso

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

24-07-2014

US biotech firm Biogen Idec said that the European Commission has approved its subcutaneous injectable…

Biogen IdecCytokinesMultiple sclerosisNeurologicalPharmaceuticalPlegridyRegulationUSA

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

15-07-2014

Portuguese drugmaker BIAL and Brazil-based moksha8 have entered an exclusive license for the commercialization…

BIALBrazileslicarbazepineExaliefLicensingMexicoMoksha8NeurologicalPharmaceuticalPortugalZebinix

1 to 25 of 777 results

Back to top